Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02749019|
Recruitment Status : Unknown
Verified April 2016 by Peking Union Medical College Hospital.
Recruitment status was: Recruiting
First Posted : April 22, 2016
Last Update Posted : April 22, 2016
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Drug: 68Ga-NOTA-BBN-RGD||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||68Ga-NOTA-BBN-RGD PET/CT in Breast Cancer Patients|
|Study Start Date :||July 2015|
|Estimated Primary Completion Date :||July 2018|
Experimental: 68Ga-NOTA-BBN-RGD PET/CT
The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
- Standardized uptake value of 68Ga-NOTA-BBN-RGD in breast cancer [ Time Frame: 1 year ]The semiquantitative analysis will be performed by the same person for all the cases, and the standardized uptake value (SUV) of the tracer in breast cancer will be measured.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02749019
|Contact: Zhaohui Zhu, MD. PhD.||+86 10 email@example.com|
|Contact: Jingjing Zhang, MD. PhD||+86 10 firstname.lastname@example.org|
|Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College||Recruiting|
|Beijing, Beijing, China, 100730|
|Contact: Zhaohui Zhu, MD. PhD. +86 10 69154196 email@example.com|